Back to Quality Research
TCMDTactile Systems Technology Inc
Health Care · Medical/Dental Instruments · Small
$23.64+0.42%
As of 23 Oct 2026Mkt cap $508M
Stage 13
AVOID
Fundamentals
51.6/75
Technical
5.0/15
Independent
56.6/90
GCAE viewstructural technical damage is a hard non-actionable condition
Price
- 1M
- +3.3%
- 3M
- −14.8%
- 6M
- −5.7%
- 1Y
- +58.4%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 21.9xHist median 22.2x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 20.5x
- FCF yield
- 4.9%
Quality
- ROIC
- 12.1%
- Operating margin
- 7.6%
- FCF margin
- 12.3%
- Current ratio
- 4.0x
Growth
- Revenue growth
- +12.5%Latest FY YoY
- Revenue CAGR
- +12.2%
- EPS CAGR
- −18.4%
- FCF CAGR
- +195.8%
Capital
- Share-count trend
- +0.3%3Y annualised
- Net cash
- $67M-1.6x OCF
Annual trend
- CAGR 2021–2025
- +12.2%
- Latest · 2025
- $0B
- YoY
- +12.5%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
structural technical damage is a hard non-actionable condition
Unresolved question
Which timing read is better supported as new price and operating evidence arrives: production v2 or research v3?
Watch next
- Next earnings · 2026-11-02
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- damaged
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded